| Fallopian Tube Carcinoma

Lynparza vs Zejula

Side-by-side clinical, coverage, and cost comparison for fallopian tube carcinoma.

Deep comparison between: Lynparza vs Zejula with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZejula has a higher rate of injection site reactions vs Lynparza based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zejula but not Lynparza, including UnitedHealthcare

Category

Lynparza

Zejula

At A Glance

RouteOral

FrequencyTwice daily

ClassPARP inhibitor

RouteOral

FrequencyDaily

ClassPARP inhibitor

Indications

Carcinoma, Ovarian Epithelial
Fallopian Tube Carcinoma
Primary Peritoneal Cancer
Malignant neoplasm of breast
Adenocarcinoma of pancreas
Hormone refractory prostate cancer

Carcinoma, Ovarian Epithelial
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Dosing

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line BRCAm maintenance) 300 mg orally twice daily; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line HRD-positive, + bevacizumab) 300 mg orally twice daily with bevacizumab 15 mg/kg every 3 weeks; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent BRCAm maintenance) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.

Malignant neoplasm of breast (adjuvant, gBRCAm HER2-negative high risk early) 300 mg orally twice daily for a total of 1 year, or until disease recurrence or unacceptable toxicity.

Malignant neoplasm of breast (metastatic, gBRCAm HER2-negative) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.

Adenocarcinoma of pancreas 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.

Hormone refractory prostate cancer (HRR gene-mutated mCRPC, monotherapy) 300 mg orally twice daily with concurrent GnRH analog or prior bilateral orchiectomy; continue until disease progression or unacceptable toxicity.

Hormone refractory prostate cancer (BRCAm mCRPC, + abiraterone) 300 mg orally twice daily with abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily; continue until disease progression or unacceptable toxicity.

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line maintenance, HRD-positive) 200 mg orally once daily for patients weighing <77 kg or with platelet count <150,000/mcL; 300 mg orally once daily for patients weighing >=77 kg AND with platelet count >=150,000/mcL; start no later than 12 weeks after most recent platinum-containing regimen.

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent, germline BRCA-mutated) 300 mg orally once daily; start no later than 8 weeks after most recent platinum-containing regimen.

Contraindications

—

Drug Interactions

1148View drug interactions

845View drug interactions

Adverse Reactions

Most common (>=10%) nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, thrombocytopenia

Serious myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, venous thromboembolism, hepatotoxicity including drug-induced liver injury

Postmarketing drug-induced liver injury, hypersensitivity including angioedema, erythema nodosum, rash, dermatitis

Most common (>10%) Nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, neutropenia, decreased appetite, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, hypertension, cough, dizziness, acute kidney injury, urinary tract infection, hypomagnesemia

Serious Thrombocytopenia, anemia, MDS/AML, bone marrow suppression, hypertension, posterior reversible encephalopathy syndrome, cardiac arrest, intestinal perforation

Postmarketing Pancytopenia, hypersensitivity (including anaphylaxis), posterior reversible encephalopathy syndrome, confusional state, hallucination, cognitive impairment, non-infectious pneumonitis, photosensitivity, hypertensive crisis

Pharmacology

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1, PARP2, PARP3) involved in DNA transcription and repair; cytotoxicity occurs through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, with enhanced activity in tumor cells harboring deficiencies in BRCA1/2, ATM, or other homologous recombination repair (HRR) genes.

Niraparib is an inhibitor of PARP enzymes (PARP-1 and PARP-2) that play a role in DNA repair; inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes results in DNA damage, apoptosis, and cell death in tumor cell lines with or without BRCA1/2 deficiencies.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Lynparza